Canopy Growth (CGC) Other Non-Current Assets (2017 - 2026)
Canopy Growth (CGC) posted Other Non-Current Assets of $12.2 million for Q1 2026, down 95.77% sequentially from $287.4 million in Q4 2025, and up 6.43% YoY from $11.4 million in Q1 2025.
Canopy Growth (CGC) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Canopy Growth has reported Other Non-Current Assets for 10 years, with the latest figure at $12.2 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 6.43% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 6.43% YoY) and the FY2026 annual result came in at $12.2 million, up 6.43% from the prior year.
- Other Non-Current Assets slipped to $12.2 million in Q1 2026 per CGC's latest filing, from $287.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $359.0 million in Q4 2024 and troughed at $4.8 million in Q4 2022.
- A 5-year average of $49.7 million and a median of $12.2 million in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets slumped 60.51% in 2022, then soared 1827.17% in 2024.
- Over 5 years, Other Non-Current Assets stood at $4.8 million in 2022, then soared by 291.34% to $18.6 million in 2023, then jumped by 1827.17% to $359.0 million in 2024, then decreased by 19.95% to $287.4 million in 2025, then plunged by 95.77% to $12.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $12.2 million, $287.4 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | 12.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.09 Mn |
| Mar 31, 2026 | 12.15 Mn |
| Dec 31, 2025 | 287.36 Mn |
| Sep 30, 2025 | 12.17 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.42 Mn |
| Dec 31, 2024 | 358.98 Mn |
| Sep 30, 2024 | 13.99 Mn |
| Jun 30, 2024 | 16.49 Mn |
| Mar 31, 2024 | 5.97 Mn |
| Dec 31, 2023 | 18.63 Mn |
| Sep 30, 2023 | 26.51 Mn |
| Jun 30, 2023 | 14.52 Mn |
| Mar 31, 2023 | 14.79 Mn |
| Dec 31, 2022 | 4.76 Mn |
| Sep 30, 2022 | 11.12 Mn |
| Jun 30, 2022 | 11.34 Mn |
| Mar 31, 2022 | 12.11 Mn |
| Dec 31, 2021 | 12.05 Mn |
| Sep 30, 2021 | 7.12 Mn |